论文部分内容阅读
据2015年2月9日《中国科学报》报道,中科院广州生物医药与健康院胡文辉课题组的抗老年痴呆症候选药物GIBH130近日已完成临床前研究,正式向国家食品药品监督管理总局申请临床试验。据介绍,GIBH130能够在体外选择性抑制神经免疫细胞释放促炎症细胞因子IL-1β,并在疾病模型动物脑部抑制小胶质细胞激活和促炎症细胞因子的
According to the report of China Science Bulletin of February 9, 2015, GIBH130, a candidate drug for Alzheimer’s disease, has been recently completed the preclinical study by Hu Wenhui’s research group at the Guangzhou Institute of Biopharmaceutics and Health, Chinese Academy of Sciences. The trial formally applied to the State Food and Drug Administration for clinical trial . It is reported that GIBH130 can selectively inhibit the release of proinflammatory cytokine IL-1β in neuroimmunocytes in vitro and inhibit microglial activation and proinflammatory cytokines in the brain of disease model animals